



Virtual Conference

The 11th Asia-Pacific Primary Liver Cancer Expert Meeting

August 13-15, 2021 | www.applecongress.org



ETHICON™
PART OF THE *Johnson & Johnson* FAMILY OF COMPANIES



APPLE ACADEMY 2021



PROGRAM AT A GLANCE

GMT+09:00 (Seoul, Tokyo)

Friday, August 13, 2021	
ROOM 1	
11:00	
12:00	Opening (11:50-12:00)
	Session 1 Risk Factors, Surveillance, and Prevention (12:00-13:00)
13:00	
	Session 2 Diagnosis and Staging for HCC and CC (13:10-14:10)
14:00	
	Session 3 Liver-Directed Therapy (14:20-15:35)
15:00	
	Session 4 System Treatment for HCC and CC (15:50-16:50)
16:00	
	Closing Remarks (16:50-17:00)
17:00	APPLE Academy Satellite Symposium (17:00-17:30)
18:00	

SCIENTIFIC PROGRAM

GMT+09:00 (Seoul, Tokyo) FRIDAY, AUGUST 13, 2021

11:50-12:00	Opening Remark	<i>Jinsil Seong (President)</i>
12:00-13:00	Session 1. Risk Factors, Surveillance and Prevention	<i>Namiki Izumi (Musashino Red Cross Hospital, Tokyo)</i>
12:00-12:15	Risk Factors and Prevention (Primary, Secondary, Tertiary)	<i>Junqi Niu (Jilin Univ., Jilin)</i>
12:15-12:30	Biomarkers for HCC and CC	<i>Kwang-Hyub Han (NECA, Seoul)</i>
12:30-12:45	Current Recommendation for HCC Surveillance	<i>Young-Suk Lim (Univ. of Ulsan, Seoul)</i>
12:45-13:00	Discussion	
13:00-13:10	Break	
13:10-14:10	Session 2. Diagnosis and Staging for HCC and CC	<i>Hirohisa Yano (Kurume Univ., Kurume)</i>
13:10-13:25	Pathological Diagnosis for HCC and CC: New WHO Classification	<i>Irene Ng (The Univ. of Hong Kong, Hong Kong)</i>
13:25-13:40	Imaging for HCC and CC: Diagnosis and Response Evaluation	<i>Choon Hua Thng (National Cancer Centre Singapore, Singapore)</i>
13:40-13:55	Treatment Algorithm of Current Guidelines	<i>Ann-Lii Cheng (National Taiwan Univ., Taipei)</i>
13:55-14:10	Case Discussion	
14:10-14:20	Break	
14:20-15:35	Session 3. Liver-Directed Therapy	<i>Pierce Chow (National Cancer Centre Singapore, Singapore)</i>
14:20-14:35	Surgical Resection for HCC	<i>Kyung-Suk Suh (Seoul National Univ., Seoul)</i>
14:35-14:50	Liver Transplantation: Selection Criteria and Outcomes	<i>Albert Chan (The Univ. of Hong Kong, Hong Kong)</i>
14:50-15:05	Transarterial Chemoembolization (TACE)	<i>Jin Wook Chung (Seoul National Univ., Seoul)</i>
15:05-15:20	Local Therapy Radiotherapy for HCC	<i>Jason Chia-Hsien Cheng (National Taiwan Univ., Taipei)</i>
15:20-15:35	Case Discussion	
15:35-15:50	Break	
15:50-16:50	Session 4. Systemic Treatment for HCC and CC	<i>Chiun Hsu (National Taiwan Univ., Taipei)</i>
15:50-16:05	Systemic Therapy for HCC	<i>Han Chong Toh (National Cancer Centre Singapore, Singapore)</i>
16:05-16:20	Systemic Therapy for Cholangiocarcinoma	<i>Stephen Lam Chan (The Chinese Univ. of Hong Kong, Hong Kong)</i>
16:20-16:35	Clinical Trial Design and Analysis: Lessons from Trials of Targeted Therapy and Immunotherapy for HCC	<i>Masafumi Ikeda (National Cancer Center Hospital East, Tokyo)</i>
16:35-16:50	Discussion	
16:50-17:00	Closing Remarks	<i>Irene Ng and Chiun Hsu (Education Chairs)</i>
17:00-17:30	APPLE Academy Satellite Symposium	

APPLE ACADEMY 2021

This program is expected to become a stepping stone for our next generation of doctors and non-expert doctors who are interested in liver cancer.

Supported by





PROGRAM AT A GLANCE

GMT+09:00 (Seoul, Tokyo)

Saturday, August 14, 2021		
	ROOM 1	ROOM 2
08:00		
09:00	<p>Session 1 Epidemiology and Surveillance of HCC (08:30-10:00)</p>	
10:00	<p>Opening Remark (10:10-10:20)</p> <p>Presidential Lecture (10:20-10:50)</p>	
11:00		
12:00	<p>Session 2 Surgery and Liver Transplantation of HCC (11:00-12:30)</p>	<p>Session 3 Antiviral Therapy and HCC (11:00-12:30)</p>
13:00	<p>Satellite Symposium - Eisai (12:30-13:10)</p>	<p>Satellite Symposium - J&J and Hengrui (12:30-13:10)</p>
14:00	<p>Session 4 Locoregional Therapy for HCC: New Roles in Immunotherapy Era (13:10-14:40)</p>	<p>Session 5 Molecular Pathogenesis and Pathology of HCC (13:10-14:30)</p>
15:00	<p>Session 6 Systemic Therapy for Earlier-Stages of HCC (14:50-15:45)</p>	<p>Session 7 Imaging Diagnosis of HCC (14:50-16:10)</p>
16:00	<p>State-of-the-Art Lecture 1 (15:55-16:35)</p>	
17:00	<p>APPLE General Assembly (16:40-17:20)</p> <p>Satellite Symposium - Roche (17:20-18:00)</p>	
18:00		

08:30-10:00	Session 1. Epidemiology and Surveillance of HCC	<i>Takuji Torimura (Kurume Univ., Kurume), Do Young Kim (Yonsei Univ., Seoul)</i>
08:30-08:50	Global Epidemiology and Risk Factors of HCC	<i>Man-Fung Yuen (The Univ. of Hong Kong, Hong Kong)</i>
08:50-09:10	HCC in Patients with NASH: Epidemiology, Risk Factors, and Surveillance	<i>Ryosuke Tateishi (The Univ. of Tokyo, Tokyo)</i>
09:10-09:30	Cost-Effectiveness of HCC Surveillance	<i>Amit Singal (UT Southwestern Medical Center, Texas)</i>
09:30-09:50	Outcome of National HCC Surveillance Program in Korea	<i>Do Young Kim (Yonsei Univ., Seoul)</i>
09:50-10:00	Discussion	
10:00-10:10	Break	
10:10-10:20	Opening Remark	<i>Jinsil Seong (President, APPLE)</i>
10:20-10:50	Presidential Lecture	<i>Ann-Lii Cheng (National Taiwan Univ., Taipei)</i>
	Radiotherapy of HCC: From Palliation to Cure	<i>Jinsil Seong (Yonsei Univ., Seoul)</i>
10:50-11:00	Break	
11:00-12:30	Session 2. Surgery and Liver Transplantation of HCC	<i>Etsuro Hatano (Kyoto Univ., Hyogo), Linda Wong (Univ. of Hawaii Cancer Center, Hawaii)</i>
11:00-11:20	The Updates and Future of Liver Surgery in the New Eras of TKI Drug and Immunotherapy	<i>Kiyoshi Hasegawa (The Univ. of Tokyo, Tokyo)</i>
11:20-11:40	Surgical Management beyond the BCLC Guideline	<i>Tan To Cheung (The Univ. of Hong Kong, Hong Kong)</i>
11:40-12:00	Minimally Invasive LDLT	<i>Kyung-Suk Suh (Seoul National Univ., Seoul)</i>
12:00-12:20	Precision Therapies in Liver Transplantation for Cancer Recurrence: Biology, Genomics and Immunology	<i>Jian Zhou (Fudan Univ., Shanghai)</i>
12:20-12:30	Discussion	
12:30-13:10	Satellite Symposium - Eisai	
13:10-14:40	Session 4. Locoregional Therapy for HCC: New Roles in Immunotherapy Era	<i>Namiki Izumi (Musashino Red Cross Hospital, Tokyo), Guohong Han (Fourth Military Medical Univ., Xi'an)</i>
13:10-13:30	Chemoembolization: Changing Role in the Real World with Introduction of New Systemic Agents	<i>Toshihiro Tanaka (Nara Medical Univ., Kashihara)</i>
13:30-13:50	Future Role of Locoregional Therapy for HCC: Hepatologist's Perspective	<i>Joong-Won Park (National Cancer Center Korea, Goyang)</i>
13:50-14:10	Local Radiotherapy as an Immunomodulator in HCC	<i>Jason Chia-Hsien Cheng (National Taiwan Univ., Taipei)</i>
14:10-14:30	Abscopal Effect of Radiotherapy for HCC	<i>Hee Chul Park (Sungkyunkwan Univ., Seoul)</i>
14:30-14:40	Discussion	
14:40-14:50	Break	

14:50-15:45	Session 6. Systemic Therapy for Earlier-Stages of HCC	<i>Pierce Chow (National Cancer Centre Singapore, Singapore), Stephen Lam Chan (The Chinese Univ. of Hong Kong, Hong Kong)</i>
14:50-15:10	Role of Systemic Therapy in Early HCC Patients: Hepatologist Perspectives	<i>Masatoshi Kudo (Kindai Univ., Osaka)</i>
15:10-15:30	Systemic Therapy for Earlier-Stages of HCC: IR Perspectives	<i>Jin Wook Chung (Seoul National Univ., Seoul)</i>
15:30-15:45	Discussion	
15:45-15:55	Break	
15:55-16:35	State-of-the-Art Lecture 1.	<i>Ghassan Abou-Alfa (Memorial Sloan-Kettering Cancer Center, New York)</i>
	Tumor Immune Microenvironment in HCC	<i>Tim Greten (National Cancer Institute, Bethesda)</i>
16:35-16:40	Break	
16:40-17:20	APPLE General Assembly	
17:20-18:00	Satellite Symposium - Roche	



11:00-12:30	Session 3. Antiviral Therapy and HCC	<i>Junqi Niu (Jilin Univ., Jilin), Yong Han Paik (Sungkyunkwan Univ., Seoul)</i>
11:00-11:20	Risk Models for HCC Development under Antiviral Therapy in CHB	<i>Jia-Horng Kao (National Taiwan Univ., Taipei)</i>
11:20-11:40	Comparison of Tenofovir vs Entecavir on Reducing Incidence of HCC in CHB	<i>Jidong Jia (Capital Medical Univ., Beijing)</i>
11:40-12:00	Antiviral Therapy in Immune-Tolerant CHB: Pros	<i>Young-Suk Lim (Univ. of Ulsan, Seoul)</i>
12:00-12:20	Antiviral Therapy in Immune-Tolerant CHB: Cons	<i>Grace L. H. Wong (The Chinese Univ. of Hong Kong, Hong Kong)</i>
12:20-12:30	Discussion	
<hr/>		
12:30-13:10	Satellite Symposium - J&J and Hengrui	
<hr/>		
13:10-14:30	Session 5. Molecular Pathogenesis and Pathology of HCC	<i>Michiie Sakamoto (Keio Univ., Tokyo), Irene Ng (The Univ. of Hong Kong, Hong Kong)</i>
13:10-13:30	Intratumoural Immune Heterogeneity as a Hallmark of Tumour Evolution in HCC	<i>Valerie Chew (Duke-NUS Medical School, Singapore)</i>
13:30-13:50	Pathological and Molecular Features Related to Cancer Stemness of HCC	<i>Young Nyun Park (Yonsei Univ., Seoul)</i>
13:50-14:10	HCC Genomics Using Single Cell Analysis	<i>Irene Ng (The Univ. of Hong Kong, Hong Kong)</i>
14:10-14:30	Discussion	
<hr/>		
14:30-14:50	Break	
<hr/>		
14:50-16:10	Session 7. Imaging Diagnosis of HCC	<i>Choon Hua Thng (National Cancer Centre Singapore, Singapore)</i>
14:50-15:10	LI-RADS: Pitfalls and Problems or How to Use LR-M and Ancillary Features	<i>Victoria Chernyak (Albert Einstein College of Medicine, New York)</i>
15:10-15:25	MR Imaging Phenotype of HCC and Histologic Correlation	<i>Jin-Young Choi (Yonsei Univ., Seoul)</i>
15:25-15:45	Application of Radiomics for Primary Liver Cancer	<i>Seung Soo Lee (Univ. of Ulsan, Seoul)</i>
15:45-16:00	AI for the Prediction, Diagnosis, and Treatment of HCC	<i>Jeong-Hoon Lee (Seoul National Univ., Seoul)</i>
16:00-16:10	Discussion	



The 11th Asia-Pacific Primary Liver Cancer Expert Meeting

PROGRAM AT A GLANCE

GMT+09:00 (Seoul, Tokyo)

Sunday, August 15, 2021	
ROOM 1	ROOM 2
08:00 Satellite Symposium - Eisai (08:00-09:00)	
09:00 Session 8 Multidisciplinary Approach in Vascular Invasive HCC (09:00-10:30)	Session 9 Cholangiocarcinoma (09:00-10:10)
11:00 Session 10 Systemic Therapy for Advanced HCC (10:40-12:10)	Session 11 Abstract Oral Presentation (10:40-12:00)
12:00 State-of-the-Art Lecture 2 (12:10-12:50)	
13:00 Wrap-up and Closing (12:50-13:00)	
14:00	



08:00-09:00	Satellite Symposium - Eisai	
09:00-10:30	Session 8. Multidisciplinary Approach in Vascular Invasive HCC	<i>Kwang-Hyub Han (NECA, Seoul), Norihiro Kokudo (National Center for Global Health and Medicine, Tokyo)</i>
09:00-09:20	Hepatologist Perspectives	<i>Jeong Won Jang (The Catholic Univ. of Korea, Seoul)</i>
09:20-09:40	Surgeon Perspectives	<i>Norihiro Kokudo (National Center for Global Health and Medicine, Tokyo)</i>
09:40-10:00	Interventional Oncologist Perspectives	<i>Chien-An Liu (Taipei Veterans General Hospital, Taipei)</i>
10:00-10:20	Radiation Oncologist Perspectives	<i>Laura Dawson (Univ. of Toronto, Toronto)</i>
10:20-10:30	Discussion	
10:30-10:40	Break	
10:40-12:10	Session 10. Systemic Therapy for Advanced HCC	<i>Sheng-Long Ye (Fudan Univ., Shanghai), Masatoshi Kudo (Kindai Univ., Osaka)</i>
10:40-11:00	Systemic Therapy for HCC: What Will Be the Next	<i>Ann-Lii Cheng (National Taiwan Univ., Taipei)</i>
11:00-11:20	Tumor Immune Microenvironment-Based Immunotherapy	<i>Ghassan Abou-Alfa (Memorial Sloan-Kettering Cancer Center, New York)</i>
11:20-11:40	Combination Immunotherapy with Anti-VEGF Multikinase Inhibitor	<i>Richard Finn (Univ. of California LA, LA)</i>
11:40-12:00	Combination Immunotherapy with Anti-CTLA-4 Antibody	<i>Thomas Yau (The Univ. of Hong Kong, Hong Kong)</i>
12:00-12:10	Discussion	
12:10-12:50	State-of-the-Art Lecture 2	<i>Jinsil Seong (Yonsei Univ., Seoul)</i>
	Radiation and Checkpoint Blockade Immunotherapy	<i>Andrew Sharabi (The Univ. California San Diego, San Diego)</i>
12:50-13:00	Wrap-up and Closing <i>Chih-Hung Hsu (Secretary General, APPLE)</i>	

09:00-10:10	Session 9. Cholangiocarcinoma	<i>Chiun Hsu (National Taiwan Univ., Taipei), Masafumi Ikeda (National Cancer Center Hospital East, Tokyo)</i>
09:00-09:20	Update of Combined Hepatocellular-Cholangiocarcinoma	<i>Matthew Yeh (Univ. of Washington, Seattle)</i>
09:20-09:40	Progress of Chemotherapy and Targeted Therapy in Cholangiocarcinoma	<i>Masafumi Ikeda (National Cancer Center Hospital East, Tokyo)</i>
09:40-10:00	Immunotherapy for Cholangiocarcinoma: Hope or Hype?	<i>Andrew Zhu (Jiahui International Cancer Center, Shanghai)</i>
10:00-10:10	Discussion	
10:10-10:40	Break	
10:40-12:00	Session 11. Abstract Oral Presentation	<i>Chih-Hung Hsu (National Taiwan Univ., Taipei), Do Young Kim (Yonsei Univ., Seoul)</i>
10:40-10:50	Comparisons of Three Serum Biomarkers Alone and in Combination for Detection of HCC in Patients with Nonalcoholic Fatty Liver Disease: A Multicenter Case-Control Study	<i>Tian Yang (Second Military Medical Univ., Shanghai)</i>
10:50-11:00	Single-Cell RNA Sequencing Shows the Immunosuppressive Landscape and Tumor Heterogeneity of HBV-Associated HCC	<i>Daniel Wai-Hung Ho (The Univ. of Hong Kong, Hong Kong)</i>
11:00-11:10	Liver Transplantation vs Partial Hepatectomy for Stage T2 Multifocal HCC: A Propensity-Score Matched Analysis	<i>Kliment Bozhilov (Queen's Medical Center, Hawaii)</i>
11:10-11:20	Combined Stereotactic Body Radiotherapy (SBRT) and Immunotherapy vs SBRT in Locally Advanced HCC: Propensity Score Matching Analysis	<i>Chiang Chi Leung (The Univ. of Hong Kong, Hong Kong)</i>
11:20-11:30	Stereotactic Ablative Body Radiotherapy for Oligometastatic HCC: A Multi-Institutional Retrospective Study (KROG 20-04)	<i>Tae Hyung Kim (Eulji Univ., Seoul)</i>
11:30-11:40	Transcatheter Arterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable HCC (TACTICS-L) in Japan: Interim Analysis	<i>Issei Saeki (Yamaguchi Univ., Yamaguchi)</i>
11:40-11:50	IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib by Baseline Varices Status in Patients with HCC	<i>Philippe Merle (Hospital La Croix-Rousse, Lyon)</i>
11:50-12:00	Nivolumab Plus Ipilimumab (N+I) as Neoadjuvant Therapy for Potentially Resectable HCC	<i>Yung-Yeh Su (National Health Research Institute, Taiwan)</i>

ORAL PRESENTATION

GMT+09:00 (Seoul, Tokyo) SUNDAY, AUGUST 15, 2021

OP-01	Comparisons of Three Serum Biomarkers Alone and in Combination for Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Multicenter Case-Control Study <i>Tian Yang (Second Military Medical University, China)</i>
OP-02	Single-Cell RNA Sequencing Shows the Immunosuppressive Landscape and Tumor Heterogeneity of HBV-Associated Hepatocellular Carcinoma <i>Daniel Wai-Hung Ho (The University of Hong Kong, Hong Kong)</i>
OP-03	Liver Transplantation versus Partial Hepatectomy for Stage T2 Multifocal Hepatocellular Carcinoma: A Propensity-Score Matched Analysis <i>Kliment Bozhilov (Queen's Medical Center, USA)</i>
OP-04	Combined Stereotactic Body Radiotherapy (SBRT) and Immunotherapy versus SBRT in Locally Advanced Hepatocellular Carcinoma: Propensity Score Matching Analysis <i>CHIANG Chi Leung (The University of Hong Kong, Hong Kong)</i>
OP-05	Stereotactic Ablative Body Radiotherapy for Oligometastatic Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 20-04) <i>Tae Hyung Kim (Eulji University, South Korea)</i>
OP-06	Transcatheter Arterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma (TACTICS-L) in Japan: Interim Analysis <i>Issei Saeki (Yamaguchi University, Japan)</i>
OP-07	IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib by Baseline Varices Status in Patients with Hepatocellular Carcinoma (HCC) <i>Philippe Merle (University Hospital La Croix-Rousse, France)</i>
OP-08	Nivolumab Plus Ipilimumab (N+I) as Neoadjuvant Therapy for Potentially Resectable Hepatocellular Carcinoma (HCC) <i>Yung-Yeh Su (National Health Research Institute, Taiwan)</i>

FREE PAPER VOD PRESENTATION

Artificial Intelligence (AI)

FV-01	Automated Segmentation on Multiphasic Computed Tomography Simulation in Radiotherapy to Liver Cancer Using Three-Dimensional Deep Neural Networks <i>Shao-Lun Lu (National Taiwan University, Taiwan)</i>
-------	--

Cell Biology and Translational Research

FV-02	YAP/TAZ Expression in Hepatocellular Carcinoma (HCC) and Effects of YAP/TAZ Inhibition on HCC <i>Sojung Han (Eulji University, South Korea)</i>
FV-03	Orchestrating the Spatial and Single-Cell Immune Landscape of Colorectal Cancer Liver Metastasis <i>Yingcheng Wu (Fudan University, China)</i>

FREE PAPER VOD PRESENTATION

FV-04	CircTUBD1 Regulates Radiation-induced Hepatic Stellate Cell Activation and Profibrotic Response via a CircTUBD1/Micro-203a-3p/Smad3 Positive Feedback Loop <i>Hao Niu (Fudan University, China)</i>
FV-05	Long Non-Coding RNA LINC00601 Contributes to Oxaliplatin Resistance of Hepatocellular Carcinoma Cells via Targeting GADD45A Gene Pathways <i>Keshu Hu (Fudan University, China)</i>

Diagnosis and Liver Imaging

FV-06	Early Complete Tumor Response as a Survival Predictor In Hepatocellular Carcinoma Patients Receiving Stereotactic Body Radiation Therapy <i>Qi-Qiao Wu (Fudan University, China)</i>
--------------	---

Epidemiology and Surveillance

FV-07	Portal Vein Thrombosis in Pakistani Population with Hepatocellular Carcinoma – Prevalence and Risk Factors <i>Tayyab Siddiqui (Aga Khan University, Pakistan)</i>
--------------	--

Molecular Pathogenesis and Pathology

FV-08	Dysregulation of RaI α Signaling through Dual Regulatory Mechanisms Exerts Its Oncogenic Functions in Hepatocellular Carcinoma <i>Lu Tian (The University of Hong Kong, Hong Kong)</i>
FV-09	Cancer Testis Antigen PAGE4 on Tumor-associated Macrophages Promotes Invasion and Metastasis of CTNNB1-mutated Hepatocellular Carcinoma via CD36 <i>Juan Zhang (Fudan University, China)</i>
FV-10	Activation of the NLRP3 Inflammasome in Hepatitis C Virus-Related Hepatocellular Carcinoma: Relation to Oxidative Stress and Tumor Progression <i>Hoda El Aggan (Alexandria University, Egypt)</i>

Staging and Prognosis

FV-11	Pattern and Clinical Significance of Lymph Node Metastasis from Hepatocellular Carcinoma <i>Byung Min Lee (Yonsei University, South Korea)</i>
FV-12	A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma <i>Shu-Yein Ho (Min-Sheng General Hospital, Taiwan)</i>
FV-13	Identification of a Pyroptosis-Related Gene Signature for Predicting Overall Survival and Response to Immunotherapy in Hepatocellular Carcinoma <i>Zheng Su Su (Fudan University, China)</i>

Treatment: Clinical Trials

FV-14	Lenvatinib Plus Pembrolizumab for Patients with Previously Treated Biliary Tract Cancers in the Multicohort Phase 2 LEAP-005 Study <i>Hyun Cheol Chung (Yonsei University, South Korea)</i>
FV-15	Atezolizumab Plus Bevacizumab (A+B) for Patients with Unresectable Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection with High Viral Load <i>San-Chi Chen (Taipei Veterans General Hospital, Taiwan)</i>

Treatment: Novel Target or Experimental Therapy

FV-16	Nano-delivery of Simvastatin to Liver Sinusoidal Endothelial Cells Inhibits Hepatocellular Carcinoma via Tumor Microenvironment Remodeling <i>Zhuo Yu (Shanghai University of Traditional Chinese Medicine, China)</i>
FV-17	Bufalin Stimulates Immune Response in Hepatocellular Carcinoma by Reprogramming Tumor-Infiltrating Macrophage toward M1 Phenotype <i>Hai Feng (Shanghai University of Traditional Chinese Medicine, China)</i>

Treatment: Surgical Resection and Transplantation

FV-18	Outcomes of Living Donor Liver Transplantation in Patients with a History of Ruptured Hepatocellular Carcinoma <i>Suk Kyun Hong (Seoul National University, South Korea)</i>
FV-19	Surgical Outcomes of Fibrolamellar Hepatocellular Carcinoma Patients: SEER Database Study <i>Tomoki Sempokuya (University of Nebraska Medical Center, USA)</i>
FV-20	Comparison of Clinical Outcome between Minimally Invasive and Open Hepatectomy at High Difficulty Score for Hepatocellular Carcinoma <i>Kelvin K.C. Ng (The Chinese University of Hong Kong, Hong Kong)</i>
FV-21	Long-term Survival of Elderly Patients Undergoing Curative Liver Resection for Early-Stage Hepatocellular Carcinoma: An International Multicenter Competing Risk Analysis <i>Tian Yang (Second Military Medical University, China)</i>

Treatment: Systemic or Targeted Therapy

FV-22	Early Serum Tumor Marker Responses Predict the Efficacy of Lenvatinib Plus an Anti-PD-1 Antibody in Unresectable Hepatocellular Carcinoma <i>Xiao-Dong Zhu (Fudan University, China)</i>
FV-23	Prognosis and Second-Line Treatment Outcome of Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab and Bevacizumab Treatment <i>Ching-Tso Chen (National Taiwan University, Taiwan)</i>
FV-24	Effects of Combination Therapy using Lenvatinib and an Anti-PD-1 Antibody on Liver Function in Patients with Advanced Hepatocellular Carcinoma <i>Ying-Hao Shen (Fudan University, China)</i>

FREE PAPER VOD PRESENTATION

FV-25	Chemoprevention of Recurrent Hepatocellular Carcinoma after Liver Resection May Be Possible with Aspirin in Diabetic Patients <i>Larry Ray Hromalik (University of Hawaii, USA)</i>
FV-26	Adjuvant Lenvatinib After Radical Resection in Patients with Hepatocellular Carcinoma (HCC): Preliminary Analysis of a Prospective, Multi-Center, Single-Arm Study <i>Hui-Chuan Sun (Fudan University, China)</i>
FV-27	Lenvatinib (LEN) plus Anti-PD-1 Antibodies in Patients with Unresectable Hepatocellular Carcinoma (uHCC) Who Progressed on Front-Line LEN: Real-World Data from China <i>Yi Chen (Fudan University, China)</i>

Treatment: Transarterial Approach/Percutaneous Ablative Therapy /Radiation Therapy

FV-28	Liver-Directed Concurrent Chemoradiotherapy Versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus <i>Jina Kim (Yonsei University, South Korea)</i>
FV-29	Etiology-Dependent Tumor Control Probability Model after Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study <i>Nalee Kim (Sungkyunkwan University, South Korea)</i>
FV-30	Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and Right Atrium Treated with Palliative Radiation Therapy and Lenvatinib <i>Adeodatus Vito Nicanor (Makati Medical Center, Philippines)</i>
FV-31	Development and Validation of A Novel Online Calculator for Estimating Survival Benefit of Adjuvant Transcatheter Arterial Chemoembolization in Patients Undergoing Surgery for Hepatocellular Carcinoma <i>Tian Yang (Eastern Hepatobiliary Surgery Hospital, China)</i>
FV-32	Development of a Prognostic Scoring System for Hepatocellular Carcinoma Patients with Main Portal Vein Tumor Thrombus Undergoing Conventional Transarterial Chemoembolization: An Analysis of 173 Patients <i>Jing-huan Li (Fudan University, China)</i>
FV-33	Development of a Prognostic Score for Recommended TACE Candidates with Hepatocellular Carcinoma Spontaneous Rupture <i>Jixue Zou (Fudan University, China)</i>
FV-34	Establishment of a Nomogram for Prognostic Prediction in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization <i>Zhongchen Li (Fudan University, China)</i>

Other Hepatobiliary Diseases

FV-35	Via mTOR Signaling Pathway LONP1 Protects Hepatocyte Oxidative Damage through Increase of Gluconeogenesis <i>Mu-Chen Wu (Beijing You-An Hospital, China)</i>
--------------	---

E-POSTER EXHIBITION

Biomarkers

PE-01	Sarcopenia and Myosteatosis Are Associated with Survival Outcomes in Patients with Hepatocellular Carcinoma Receiving Immunotherapy <i>Bang-Bin Chen (National Taiwan University, Taiwan)</i>
PE-02	An Immune-Related Gene Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma <i>Feng Zhang (Fudan University, China)</i>
PE-03	Matrix Stiffness Up-regulates the expression of SCD1 and Promotes the Invasion of Hepatocellular Carcinoma Cells <i>Hua-Hua Liu (Fudan University, China)</i>
PE-04	Role of Interleukin-7 in the Development of and Recovery from Radiation-Induced Lymphopenia: A Post-Hoc Analysis of a Prospective Cohort <i>Hwa Kyung Byun (Yonsei University, South Korea)</i>
PE-05	Expression of USP46 and Its Prognostic Role in Hepatocellular Carcinoma: Analysis Based on the Data-Mining <i>WU Yanfang (Fudan University, China)</i>

Cell Biology and Translational Research

PE-06	Single-Cell Transcriptomic Analysis Reveals Two Molecularly and Clinically Distinct Subtypes of Intrahepatic Cholangiocarcinoma <i>Guohe Song (Fudan University, China)</i>
PE-07	Significance of TERT Genetic Alterations and Telomere Length in Hepatocellular Carcinoma <i>Jin Seoub Kim (The Catholic University of Korea, South Korea)</i>

Cirrhosis and Related Complications

PE-08	Comparison of the AIMS65 to Liver Severity Score in Predicting Mortality and Rebleeding in Liver Cirrhosis Patients with Acute Variceal Bleeding <i>Myeong Jun Song (The Catholic University of Korea, South Korea)</i>
-------	--

Diagnosis and Liver Imaging

PE-09	Imaging Findings of Liver MRI with Liver-Specific Contrast and the Risk of Hepatocellular Carcinoma <i>Jong-In Chang (Sungkyunkwan University, South Korea)</i>
PE-10	Category M of the Liver Imaging Reporting and Data System Version 2018 using MRI: A Systematic Review and Meta-Analysis <i>Sunyoung Lee (Yonsei University, South Korea)</i>
PE-11	Utility of Ancillary Magnetic Resonance Imaging Features in Liver Imaging and Reporting Data System Treatment Response Algorithm for Hepatocellular Carcinoma <i>Yeun-Yoon Kim (Yonsei University, South Korea)</i>

Molecular Pathogenesis and Pathology

PE-12	Lung and Lymph Node Metastases from Hepatocellular Carcinoma: Comparison of Pathological Aspects <i>Ha Young Woo (National Cancer Center, South Korea)</i>
PE-13	Nrf2 Imparts Ferroptosis Resistance in Hepatocellular Carcinoma Via ASPH/PI3K/Akt Axis <i>Jing Wu (Capital Medical University, China)</i>
PE-14	YAP Inactivation in Estrogen Receptor Alpha-Positive Hepatocellular Carcinoma with Less Aggressive Behavior <i>Taek Chung (Yonsei University, South Korea)</i>
PE-15	Fast Computational Viral Integration Detection in HBV-Associated Hepatocellular Carcinoma <i>Xueying Lyu (The University of Hong Kong, Hong Kong)</i>

Staging and Prognosis

PE-16	Prognostic Nomogram of Recurrent Hepatocellular Carcinoma Treated with Radiofrequency Ablation <i>Diyang Xie (Fudan University, Hong Kong)</i>
PE-17	Prognostic Significance of TGR in Patients with Huge Hepatocellular Carcinoma undergoing Transcatheter Arterial Chemoembolization <i>Guobin Chen (Fudan University, China)</i>
PE-18	The Overall Survival of Hepatocellular Carcinoma after Resection according to the Cause of Liver Disease <i>Hyun Woong Lee (Yonsei University, South Korea)</i>
PE-19	The Predictive Value of Enhanced Liver Fibrosis (ELF) Score for the Patient with Hepatocellular Carcinoma after Liver Resection <i>Munseok Choi (Yonsei University, South Korea)</i>

Treatment: Novel Target or Experimental Therapy

PE-20	Mid-Line 1 Interacting Protein 1 (MID1IP1) Promotes Metastasis via AMPK-Mediated MMP9 Signalling in Hepatocellular Carcinoma <i>Elley Yung-Tuen Chiu (The University of Hong Kong, Hong Kong)</i>
-------	--

Treatment: Systemic or Targeted Therapy

PE-21	TACE Treatment in Combination with or without Sorafenib in HCC Patients with BCLC Stage B: A Systematic Review <i>Aldi Nanda Kurniawan (Pelita Harapan University, Indonesia)</i>
PE-22	Modified ALBI Grade for Predicting Hepatocellular Carcinoma Prognosis among Who Treated with ICI plus TKI – A Real-World Practice <i>Hong Chen (Fudan University, China)</i>

PE-23	Combination Therapy of Tyrosine Kinase Inhibitor and Immunotherapy for Patients with Unresectable Hepatocellular Carcinoma: Single Center Experience <i>Shou-Wu Lee (Taichung Veterans General Hospital, Taiwan)</i>
--------------	---

Treatment: Transarterial Approach/Percutaneous Ablative Therapy /Radiation Therapy

PE-24	Efficacy of Radiofrequency Ablation vs Percutaneous Ethanol Injection in Hepatocellular Carcinoma Patients: A Systematic Review <i>Audrey Hadisurya (Pelita Harapan University, Indonesia)</i>
PE-25	Successful Hepatocellular Carcinoma Downstaging with Preoperative Stereotactic Body Radiotherapy: Retrospective Evaluation of Pathologic Response <i>Gong Li (Beijing Tsinghua University, China)</i>
PE-26	Efficacy and Safety of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Elderly Patients <i>Jinhong Jung (University of Ulsan, South Korea)</i>
PE-27	Local Intervention for Skull Base Metastasis in Hepatocellular Carcinoma <i>Kangpyo Kim (Yonsei University, South Korea)</i>
PE-28	Applying a Thoracoabdominal Aorta CTA-Based Nomogram Model to Identify Good Candidates for Transradial Approach Chemoembolization in Patients with Liver Cancer: A Pilot Study <i>Miao Li (Fudan University, China)</i>
PE-29	Adjuvant Radiotherapy for Extrahepatic Cholangiocarcinoma: A Quality Assessment-Based Meta-Analysis <i>Seo Hee Choi (Yonsei University, South Korea)</i>
PE-30	A Comparative Study of Microwave and Radiofrequency Ablation Therapy for Hepatocellular Carcinoma <i>Soon Kyu Lee (The Catholic University of Korea, South Korea)</i>
PE-31	Ultrasound Fusion Imaging (UFI) 101 for Liver Tumours <i>Sudharsan Madhavan (Singapore General Hospital, Singapore)</i>
PE-32	Stereotactic Body Radiotherapy using Helical Tomotherapy for Hepatocellular Carcinoma as Treatment Stage Alternative Approach <i>Sun Hyun Bae (Soonchunhyang University, South Korea)</i>
PE-33	Radiofrequency Ablation versus Combined Transarterial Chemoembolization for Massive Recurrence of Early Unifocal Hepatocellular Carcinoma <i>Weike Chu (Tianjin Medical University, China)</i>

Viral Hepatitis

PE-34	A Nationwide Prospective Cohort Study on Chronic Hepatitis B in Korea: An Interim Analysis <i>Jae Seung Lee (Yonsei University, South Korea)</i>
--------------	---

E-POSTER EXHIBITION

PE-35	Comparison of the Occurrence of Hepatocellular Carcinoma in Patients of Chronic Hepatitis B Treated with Entecavir and Tenofovir <i>Tae Hyung Kim (Korea University, South Korea)</i>
--------------	--

Other Hepatobiliary Diseases

PE-36	Role of Adjuvant Chemoradiotherapy in Perihilar Bile Duct Cancer: A Single Institutional Long-Term Follow up Analysis <i>Choong-won Lee (Seoul National University, South Korea)</i>
PE-37	Phase 2 Multicohort Study of Lenvatinib Plus Pembrolizumab in Patients with Previously Treated Selected Solid Tumors: LEAP-005 Pancreatic Cancer Cohort <i>Hyun Cheol Chung (Yonsei University, South Korea)</i>
PE-38	Benefit of Adjuvant Radiotherapy for Gallbladder Cancer: A Comparability-Based Meta-Analysis <i>Seo Hee Choi (Yonsei University, South Korea)</i>
PE-39	Gall Bladder Perforation In Cardiac Patient <i>Muhammad Zakria (Wapda Medical Complex, Pakistan)</i>

Miscellaneous

PE-40	Hepatectomy for Liver Cancer under Influence of COVID-19 in a Regional Hospital in Hong Kong <i>Yue Sun Cheung (North District Hospital, Hong Kong)</i>
--------------	--